Compass Therapeutics price target raised to $24 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Compass Therapeutics (CMPX) to $24 from $10 and keeps a Buy rating on the shares. The company announced positive topline results on the primary efficacy endpoint for COMPANION-002, its ongoing Phase 2/3 randomized study of tovecimig in combination with paclitaxel in patients with advanced biliary tract cancer, the analyst tells investors in a research note. The firm says the data presented highlight a “positive, important step forward” in establishing the potential of tovecimig to become standard of care in second-line BTC.